Summary: In a phase 2b dose-ranging trial in adults with obesity, the oral GLP-1 agonist danuglipron produced significant, dose-dependent weight loss of up to about 13% versus placebo, but with high discontinuation rates driven by gastrointestinal adverse events.
PICO Summary
| Element | Detail |
|---|---|
| Population | 628 adults with obesity, without diabetes (aged 18–75). |
| Intervention | Danuglipron (PF-06882961), an oral small-molecule GLP-1 agonist, twice daily (escalated to 40–200 mg) for 26 or 32 weeks (n=536). |
| Comparison | Placebo twice daily (n=90). |
| Outcome | Significant placebo-adjusted weight reductions across all doses, from -5.0% (90% CI -6.8 to -3.2) to -12.9% (90% CI -16.1 to -9.5). Only 39.3% completed treatment; about 38% discontinued for adverse events (mainly nausea and vomiting), with higher GI rates at higher doses. |
Danuglipron for obesity
Phase 2b RCT · obesity · 26–32 weeks
Oral danuglipron gave dose-dependent weight loss up to about 13% versus placebo, but fewer than four in ten completed treatment and nearly four in ten stopped for gastrointestinal adverse events.
Expert Commentary
This trial captures both the promise and the problem of an oral GLP-1 agonist. The efficacy signal is real and, at the top dose, competitive with injectables, which matters because a pill that matched injectable weight loss would be transformative for access and acceptability. But the tolerability story is sobering: fewer than four in ten participants completed treatment and nearly four in ten stopped because of adverse effects, predominantly the expected nausea and vomiting, worse at higher doses. That is the central tension, the doses that drive weight loss are the ones patients struggle to stay on, and the twice-daily oral formulation tested here compounds the exposure problem. It is worth noting this molecule’s development was subsequently halted, which contextualises the result. Can I use this with my patients? Not yet, and possibly not in this form. The study is a useful proof that oral small-molecule GLP-1 agonism can produce meaningful weight loss, but it also shows that tolerability and formulation, not just potency, will decide whether oral agents reach the clinic. For now, established injectable and emerging better-tolerated oral agents remain the practical options.
References
Buckeridge C, Cobain S, Bays HE, et al. Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: a randomized, placebo-controlled, dose-ranging phase 2b study. Diabetes Obes Metab. 2025;27(9):4915–4926. doi:10.1111/dom.16534